[Company Announcement: Proposed Appointment of Supervisor and Supplemental Announcement Regarding Annual Reports](index=1&type=section&id=%E5%85%AC%E5%8F%B8%E5%85%AC%E5%91%8A%EF%BC%9A%E5%BB%BA%E8%AD%B0%E5%A7%94%E4%BB%BB%E7%9B%A3%E4%BA%8B%E5%8F%8A%E6%9C%89%E9%97%9C%E5%B9%B4%E5%A0%B1%E4%B9%8B%E8%A3%9C%E5%85%85%E5%85%AC%E5%91%8A) This announcement details the proposed appointment of a new supervisor and clarifies supervisor remuneration in annual reports [Proposed Appointment of Supervisor](index=1&type=section&id=%E5%BB%BA%E8%AD%B0%E5%A7%94%E4%BB%BB%E7%9B%A3%E4%BA%8B) The company proposes Ms. Wang Yong as shareholder representative supervisor and chairperson, pending shareholder approval - The company's board of supervisors recommends appointing Ms. Wang Yong as a supervisor and chairperson of the second board of supervisors[3](index=3&type=chunk) - This appointment is subject to approval by an ordinary resolution at the general meeting of shareholders[3](index=3&type=chunk)[8](index=8&type=chunk) - As a shareholder representative supervisor, Ms. Wang will not receive any remuneration from the company[7](index=7&type=chunk) [Supervisor Candidate Background: Ms. Wang Yong](index=1&type=section&id=%E7%9B%A3%E4%BA%8B%E5%80%99%E9%81%B8%E4%BA%BA%E7%9A%84%E8%83%8C%E6%99%AF) Ms. Wang Yong, 52, CFO of Lepu Medical, possesses CPA qualifications and audit experience Key Background Information | Item | Content | | :--- | :--- | | Age | 52 | | Nationality | China | | Current Key Positions | CFO, Senior Deputy General Manager at Lepu Medical (Controlling Shareholder, 300003.SZ) | | Past Key Experience | Senior Audit Manager, Audit Department, PwC Zhong Tian CPAs Beijing Branch (1996-2007) | | Professional Qualifications | Certified Public Accountant (obtained 2001) | Shareholding Information | Company Held | Capacity | Shares/Percentage | | :--- | :--- | :--- | | The Company | Via Employee Stock Ownership Platform | 147,221 shares (approx. 0.04%) | | Lepu Medical | Beneficial Owner | 191,700 shares (approx. 0.01%) | | Beijing Lepu Diagnostics | Via Employee Stock Ownership Platform | 383,955 shares (approx. 0.10%) | - Ms. Wang holds director or supervisor positions in several affiliated or non-affiliated companies, including Sichuan Ruijian Medical, Shanghai Lepu Yunzhi, and Sino-American Huashitong[4](index=4&type=chunk) [Supplemental Announcement Regarding Annual Reports](index=3&type=section&id=%E6%9C%89%E9%97%9C%E5%B9%B4%E5%A0%B1%E4%B9%8B%E8%A3%9C%E5%85%85%E5%85%AC%E5%91%8A) The company clarifies that total remuneration paid to all supervisors for fiscal years 2022-2024 was zero - This announcement provides supplementary information for the company's 2022, 2023, and 2024 annual reports[9](index=9&type=chunk) Total Remuneration Paid to All Supervisors | Fiscal Year | Total Remuneration Paid to All Supervisors | | :--- | :--- | | 2022 | Zero | | 2023 | Zero | | 2024 | Zero | - The disclosed total remuneration of zero covers all items, including fees, basic salary, housing allowances, in-kind benefits, and bonuses[9](index=9&type=chunk)

Summary of Key Points from Conference Call Records Industry Overview - The conference call discusses the **domestic medical device industry**, highlighting advancements in various companies and their innovative products. Key Companies and Their Innovations 1. **Peijia Medical** - The shockwave balloon technology shows a **30%-50% efficacy** in early clinical trials for treating aortic valve calcification [1] - The transcatheter aortic valve replacement product **Mona Q** has enrolled **9 patients** in the global Fame clinical trial, with no deaths or strokes reported during long-term follow-up. It has received **IDE clinical approval** in the U.S. and is expected to advance to U.S. clinical trials within the year [2][4] 2. **Jianxi Technology** - The tricuspid valve replacement product has completed clinical registration trials in Europe with a **97% success rate** and is expected to receive CE certification by **2025** [1][3] 3. **Xenon Medical** - The self-expanding intracranial drug-eluting stent has a **restenosis rate of only 1.7%-1.87%** and a **100% surgical success rate**. Approval is anticipated this year, with a market exclusivity period of **1.5 to 2 years** [1][6][7] 4. **HeartTech Medical** - Leading market share in domestic occluder products with a series of **four generations of biodegradable occluders**. The aortic valve product has been approved for commercialization since Q1 [1][8] 5. **Qiming Medical** - Four TAVI products have been approved and marketed in over **ten countries**. New TAVI products are under development, with expectations for a tricuspid valve replacement product to be approved in Europe by **2027** [1][9] Market Trends and Future Outlook - The medical device sector is expected to see a **catalyst for growth** in the second half of the year due to potential equipment upgrades, particularly in **3.0T MRI and 64-slice CT** products [2][17] - Companies like **Huitai Medical** are projected to have strong performance due to new product launches and market expansion [11][23] Competitive Strategies - Domestic medical device companies are enhancing their international competitiveness through: - **Patent breakthroughs** and early clinical trials [4] - Focusing on less crowded market segments for differentiation [4] - Collaborations with international firms to leverage global networks for faster commercialization [5] Financial Performance Expectations - Companies such as **Huitai Medical** and **Mingrui Medical** are expected to show strong growth in the second half of the year, despite some companies facing short-term pressures due to high bases from previous years [10][11][15] - The **IVD sector** is experiencing pressure from policy changes, but improvements are anticipated in the latter half of the year as companies adjust pricing strategies [28] Regulatory and Policy Impact - The medical industry is facing challenges from **DRG cost control policies** and increased compliance requirements, impacting overall performance and cash flow [33] Conclusion - The domestic medical device industry is poised for growth with innovative products and strategic collaborations, despite facing regulatory challenges and market competition. Companies are actively seeking to enhance their international presence and capitalize on emerging market opportunities.

Group 1 - The article discusses the first real theater-based neuroaesthetic experiment in China, conducted at Tsinghua University, where eight volunteers wore portable EEG devices while watching a dance performance to capture their neural activity in real-time [3][6]. - The NeuroHUB platform, developed by Boruikang, is highlighted for its ability to achieve millisecond-level synchronization of EEG and physiological signals in a real-world setting, marking a significant advancement in neuroaesthetic research [5][6]. - The experiment demonstrated that audience engagement significantly increases brain activity, revealing the neural connections between emotional responses and artistic experiences [6][7]. Group 2 - NeuroHUB showcases three core advantages: wireless freedom allowing natural seating in the theater, group super-scanning enabling real-time dialogue among multiple brains, and robust interference resistance against complex electromagnetic environments [7][9]. - The platform's modular design and wireless data transmission ensure a seamless experience for participants, maintaining the purity of the artistic experience during the performance [7]. - NeuroHUB's capability to synchronize data from over ten participants simultaneously represents a breakthrough in overcoming the limitations of traditional laboratory settings [8]. Group 3 - The article also mentions advancements in medical technology, including a new integrated solution for coronary function and imaging assessments approved for market release, which combines multiple evaluation metrics for enhanced surgical decision-making [11][12]. - The development of a fully magnetic levitation artificial heart by Xinxin Medical has been recognized as one of the top ten technological advancements in Jiangsu Province, showcasing significant progress in heart failure treatment [13][15]. - The iPSC-derived CAR-NK cell therapy developed by Qihan Biotech has achieved notable clinical results in treating refractory systemic sclerosis, marking a significant milestone in autoimmune disease treatment [16][17]. Group 4 - The article highlights the introduction of two first-in-class drugs by Dige Pharmaceutical, which will be presented at major international conferences, indicating ongoing innovation in the hematology sector [21]. - The J-VALVE TF system's 12-month clinical follow-up results demonstrate superior performance compared to similar products, emphasizing the potential of Chinese-developed medical devices on the international stage [22][24]. - The article concludes with advancements in AI-driven enzyme design and biodegradable medical devices, showcasing the ongoing evolution and innovation within the healthcare and biotechnology industries [25][35].

Group 1 - The medical and pharmaceutical sector continues to perform strongly, with the Hong Kong medical ETF (159366) rising over 2% in early trading, marking a three-day increase [1] - Key stocks such as Kelaiying, Micron Medical, and Zhaoyan Pharmaceutical saw significant gains of 5.90%, 5.47%, and 4.73% respectively, contributing to a cumulative increase of 6.32% in the ETF over the past week [1] - A major policy announcement from the Central Committee and the State Council aims to improve public welfare and healthcare, including the establishment of a drug catalog adjustment mechanism and the promotion of quality healthcare resource sharing [1] Group 2 - Dongwu Securities highlights three factors that suggest 2025 will be a pivotal year for innovative drugs, including the orderly rollout of significant business development (BD) deals, expected profitability for more companies by 2026, and an improving domestic environment for innovative drugs [2] - The Chinese innovative drug market is poised for rapid growth, supported by favorable policies and international expansion, making it a highly promising sub-sector within the pharmaceutical industry [2] - The Hong Kong medical ETF (159366) focuses on unique medical segment leaders, including internet healthcare, CXO, and medical devices, and operates as a pure Hong Kong Stock Connect ETF with T+0 trading support [2]

Core Viewpoint - The article highlights the successful commercialization and clinical application of the ScienCrown transcatheter aortic valve replacement (TAVR) system developed by Lepu Medical Technology, marking a significant advancement in the treatment of aortic stenosis patients in China [2][5][10]. Company Overview - Lepu Medical Technology (Shanghai) Co., Ltd. is a leading innovator in the field of interventional medical devices for structural heart diseases, supported by the Shanghai Biomedical Investment Fund. The company went public on November 8, 2022, on the Hong Kong Stock Exchange under the stock code 02291.HK [17]. - The company focuses on the research, development, production, and marketing of interventional medical devices, with over 40 products listed and in development, covering congenital heart disease, stroke prevention, and valve treatment solutions [17]. Product Introduction - The ScienCrown TAVR system is the world's first and only self-expanding short valve product with balloon-expandable advantages, designed to address existing challenges in TAVR procedures [4][12]. - The product features 100% full release and retrieval capabilities, dual access routes, and innovative designs that significantly enhance clinical practice [4][12][15]. Clinical Application - The first commercial implantations of the ScienCrown valve have been successfully conducted in multiple clinical centers across China, demonstrating its effectiveness and safety [5][7]. - Clinical trial results indicate a procedural success rate of approximately 99.2% and a device success rate of about 98.4%, with low rates of paravalvular leak and no severe leaks reported [7][10]. Market Context - Aortic valve disease, particularly aortic stenosis (AS), is a common cardiovascular issue, especially among the elderly, with a prevalence of approximately 11.5% in patients over 60 years old [8][10]. - The number of patients with aortic stenosis and aortic regurgitation in China is projected to reach 9.3 million by 2025, with a compound annual growth rate of 2.6% from 2022 to 2025 [10].

Group 1: Hong Kong Stock Market Highlights - Giant Bio (02367) opened down over 8% due to concerns over the collagen content in its product, with a current decline of over 3% [1] - Horizon Robotics-W (09660) opened up over 3% as it officially enters the Hong Kong Stock Connect list, but is now down over 3% [1] - Fubo Group (03738) rose over 6% with a Q1 revenue growth of approximately 23%, accelerating its AI ecosystem layout [1] - Tongcheng Travel saw an initial rise of nearly 14%, reaching a historical high, with Q1 performance exceeding expectations; accommodation revenue grew by 23.3% year-on-year [1] - BYD initiated a price war with 22 models in its Dynasty and Ocean series seeing price cuts of up to 53,000 yuan, leading to declines in the entire electric vehicle sector [1] - Power stocks rose across the board, with Shanghai Electric (02727) seeing a peak increase of over 10%, currently up over 6% [1] - Semiconductor stocks performed well, with Hua Hong Semiconductor up over 2.6% and SMIC up 1.3%, amid news of asset restructuring between major semiconductor firms [1] Group 2: US Stock Market Highlights - Miniso (MNSO.US) plummeted over 17% due to a decline in profits for Q1 [3] - Intuit (INTU.US) rose over 8% as Q3 results exceeded expectations, driven by growth in its personal finance platform and accounting software [3] - Workday (WDAY.US) fell over 12% despite Q1 earnings exceeding expectations by a small margin [3] - U.S. Steel (X.US) surged over 20% as negotiations between Nippon Steel and the U.S. government reached the final stages [3] - Apple shares dropped 3% following threats from Trump regarding tariffs if production is not moved back to the U.S. [3] Group 3: Company-Specific Developments - Heart Medical (2291.HK) saw a peak increase of 28.33% during the day, with a dividend of 0.673664 HKD per share announced; the company reported a 44.78% year-on-year revenue growth for FY2024 [2]

Market Performance - As of May 26, 2025, the CSI Hong Kong Stock Connect Healthcare Index (930965) decreased by 1.59%, with mixed performance among constituent stocks [1] - The Hong Kong Medical ETF (159718) fell by 1.49%, with a latest price of 0.73 HKD, but saw a 4.68% increase over the past week as of May 23 [1] - The CSI Medical and Medical Device Innovation Index (931484) declined by 1.16%, with the Medical Innovation ETF (516820) down by 0.86% and a latest price of 0.35 HKD [4] Notable Stocks - HeartTech Medical (02291) led gains with an increase of 11.11%, while three pharmaceutical companies, including 3SBio (01530), saw declines of over 6% [1] - The top ten weighted stocks in the CSI Hong Kong Stock Connect Healthcare Index accounted for 60.54% of the index, with companies like BeiGene (06160) and WuXi Biologics (02269) among the leaders [6][8] IPO and Market Sentiment - On May 23, 2025, the chairman of Innovent Biologics (1276.HK) rang the bell at the Hong Kong Stock Exchange, marking a successful "A+H" dual listing with a first-day stock price increase of 29.4% [1] - According to a report by China Merchants Securities International, market sentiment towards the Hong Kong healthcare sector is more optimistic compared to 2024, with expectations that the IPO of Innovent Biologics will attract more global capital [2] Industry Trends - Haitong International predicts a significant turning point for the Hong Kong healthcare industry in 2025, driven by stricter regulatory policies and accelerated review processes for innovative drugs and devices [2] - The shift towards digital marketing and the increase in new product approvals are expected to lead to growth in the industry, particularly for leading companies transitioning from generics to innovative products [2]

Group 1 - The Hang Seng Medical Index ETF has shown significant liquidity with a turnover of 5.27% and a transaction volume of 13.6062 million yuan, with an average daily transaction volume of 28.9853 million yuan over the past month [2] - The ETF has experienced a notable increase in scale, growing by 1.7471 million yuan over the past week, ranking first among comparable funds, with the latest share count reaching 218 million, a new high for the past month [2] - The ETF has seen continuous net inflows over the past four days, with a maximum single-day net inflow of 6.1016 million yuan, totaling 13.3303 million yuan [2] Group 2 - The price-to-earnings ratio (PE-TTM) of the Hang Seng Medical Healthcare Index is currently at 23.35, which is in the 3.64% percentile for the past year, indicating that the valuation is lower than 96.36% of the time in the past year, suggesting a historical low [2] - The top ten weighted stocks in the Hang Seng Medical Healthcare Index include WuXi AppTec, Innovent Biologics, BeiGene, and others, collectively accounting for 56.03% of the index [2] Group 3 - The domestic medical device industry is still in a rapid development phase, with short-term impacts from medical insurance cost control potentially affecting the sector negatively, but there is optimism for innovation-driven import substitution and global development [3] - The industry is expected to see improved competitiveness among domestic companies due to policy support and technological advancements, accelerating import substitution [3] - Investors without stock accounts can consider the Hang Seng Medical Index ETF linked fund (018433) to gain exposure to investment opportunities in the Hong Kong medical sector [3]

金仕生物 全球首款预装干瓣Prostyle A® 获批上市 4月9日，金仕生物宣布由公司自主研发的 Prostyle A®经导管人工主动脉瓣膜置换系统-干法预装可回收输送 系统 获得国家药品监督管理局 （NMPA） 批准上市 （ 国械注准20253130729） 。 作为全球首款预装干瓣，金仕生物推出的新一代介入主动脉瓣Prostyle A®集成了众多瓣膜领域的前沿技 术，拥有干瓣技术、巧妙便捷的预装系统、卓越的瓣膜血流动力学性能和耐久性，优秀的输送性和通过 性，平稳的释放和可靠的锚定等特点。金仕生物自主创新的干瓣技术，在国内、欧洲、美国、日本等国家 享有专利保护。这一产品的出现，迎来中国TAVR的新时代 ——干瓣时代。 艾柯医疗 全新血流导向密网支架系统"Lattice COUPLE"成功获批 近日，艾柯医疗全新血流导向密网支架系统"Lattice COUPLE"，成功获得国家药监局批准注册 （ 注册证编 号：国械注准20253130668） 。至此， 艾柯医疗成为神经介入行业首家拥有三张密网注册证的企业 。 微光医疗 FDA 首次批准中国高端腔内介入影像设备 4月11日，微光医疗宣布其两款冠脉OCT设备及 ...

Core Viewpoint - The China Securities Index for Hong Kong Stock Connect Medical Devices shows a recent decline, but has experienced significant growth over the past three months and year-to-date [1]. Group 1: Index Performance - The China Securities Index for Hong Kong Stock Connect Medical Devices reported a recent value of 1194.94 points [1]. - Over the past month, the index has decreased by 3.48%, while it has increased by 15.43% over the last three months and 12.63% year-to-date [1]. Group 2: Index Composition - The index is composed entirely of securities listed on the Hong Kong Stock Exchange, with a sample that includes various sectors classified under the China Securities Industry Classification Standard [2]. - The index's sample shows that medical consumables account for 79.10%, medical devices for 16.57%, and in vitro diagnostics for 4.34% [2]. Group 3: Index Adjustments - The index samples are adjusted biannually, specifically on the second Friday of June and December, with weight factors fixed until the next scheduled adjustment [2]. - In cases of special events affecting the index sample, such as delisting or mergers, adjustments will be made accordingly [2].